Tezepelumab’s broad anti-inflammatory effects, due to TSLP targeting, may offer potential benefits in obese individuals with severe asthma by addressing underlying inflammation and improving asthma control, even in the absence of specific biomarkers [66,67]. This evidence concerns the gene TSLP and asthma.